Washington: US pharmaceutical firm Eli Lilly on Tuesday paused a late-stage trial of its experimental lab-produced antibody treatment against COVID-19 over an unspecified safety concern, the company said.
“Lilly is supportive of the decision by the independent DSMB (data safety monitoring board) to cautiously ensure the safety of the patients participating in this study,” a spokesperson said in a statement.
